GlassScriptPhysician profile
Thanh N Truong
NPI 1225009616
$27,632.34
in general payments reported to CMS, 2019-2025
69 companies · $3,928 in 2025
The $3,928 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,292 · 2020: $3,229 · 2021: $5,190 · 2022: $1,950 · 2023: $3,831 · 2024: $4,211 · 2025: $3,928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,945.91 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,673.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $2,447.05 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $2,398.29 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $2,097.82 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $1,914.70 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,759.49 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,035.75 | 2019-2025 | Spravato, Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,028.97 | 2019-2025 | Xifaxan, Trulance |
| Supernus Pharmaceuticals, INC. | $913.52 | 2020-2024 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $910.30 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $779.55 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $726.24 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Sanofi-Aventis U.S. LLC | $670.06 | 2019-2024 | |
| Gilead Sciences, INC. | $574.95 | 2019-2024 | Livdelzi |
| Abbott Laboratories | $541.02 | 2019-2025 | Freestyle Libre 3 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thanh Truong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.